Radiolabeled somatostatin analogs in prostate cancer
- 5 January 1997
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 24 (1) , 105-113
- https://doi.org/10.1016/s0969-8051(96)00180-1
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Molecular Pharmacology of Somatostatin‐receptor SubtypesAnnals of the New York Academy of Sciences, 1994
- A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotideEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of actionJournal of Clinical Endocrinology & Metabolism, 1993
- Differential Effects of Peptide Hormones Bombesin, Vasoactive Intestinal Polypeptide and Somatostatin Analog RC-160 on the Invasive Capacity of Human Prostatic Carcinoma CellsJournal of Urology, 1993
- Radioimmunoguided radical prostatectomy and lymphadenectomyCancer, 1993
- Cancer statistics, 1992CA: A Cancer Journal for Clinicians, 1992
- In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in ratsLife Sciences, 1991
- [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validationLife Sciences, 1991
- Radioimmunological Imaging of Metastatic Prostatic Cancer with 111 Indium-Labeled Monoclonal Antibody Pay 276Journal of Urology, 1987
- Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging.Radiology, 1987